How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,228 results for

Mean Corpuscular Volume

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Daily vs Alternate Day Iron Supplementation for Pregnant Women With Iron Deficiency Anemia

less than 11.0 or hematocrit less than 33% with ferritin 25 ug/L Age 18-64 years old. Gestational age between 12 0/7 weeks and 34 0/7 weeks. No other known causes of anemia (Folate or vit b12 deficiency anemia, sideroblastic anemia, thalassemia, sickle cell anemia, aplastic anemia, hemolytic anemia, anemia of chronic disease). Anemic patients with a low ferritin level and a mean corpuscular volume (MCV) >95 will have folate and vitamin B12 measured since some patients might have combined causes (...) studies before adding more. Daily vs Alternate Day Iron Supplementation for Pregnant Women With Iron Deficiency Anemia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03562143 Recruitment Status : Recruiting First Posted

2018 Clinical Trials

182. Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function

analytes, platelet counts, red blood cells (RBC) count, white blood cells (WBC) count, hemoglobin, hematocrit, RBC indices (mean corpuscle volume [MCV], mean corpuscle hemoglobin [MCH], and mean corpuscular hemoglobin concentration (MCHC) and differential WBC count (neutrophils, lymphocytes, monocytes, eosinophils, and basophils. Number of subjects with toxicity grading values values higher than Grade 3 or Grade 4 for hematology, Part 2 [ Time Frame: Up to 15 days ] Blood samples will be collected (...) does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03562117 Recruitment Status : Completed First Posted : June 19, 2018 Last Update Posted : January 25, 2019 Sponsor: GlaxoSmithKline Collaborator: Biomedical Advanced Research and Development Authority Information provided by (Responsible Party): GlaxoSmithKline Study Details Study Description Go to Brief Summary: This is a two-part study which will evaluate the PK, safety

2018 Clinical Trials

183. Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a

] Number of subjects with AE /SAEs leading to pembrolizumab administration delay, interruptions, and withdrawals will be summarized. Number of subjects with abnormal hematology parameters [ Time Frame: Up to 2 years ] Blood samples will be collected for the assessment of the following hematology parameters: platelet count, red blood cell (RBC) count, hemoglobin, hematocrit, mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), reticulocytes, neutrophils, lymphocytes, monocytes, eosinophils (...) Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03697824 Recruitment Status : Withdrawn (Internal decision, study will be replaced with a larger monotherapy trial) First Posted : October 5, 2018 Last Update Posted

2018 Clinical Trials

184. Bioequivalence Study Between SKF101804 Cefixime 200 Milligram (mg)/5 Milliliter (mL) Suspension Versus Cefixime 200 mg/5 mL Suspension Reference Product in Healthy Adult Subjects Under Fasting Conditions

of total Protein. Platelets, Neutrophils, Monocytes, Lymphocytes, Leucocyte, Eosinophils and Basophils at Indicated Time-points [ Time Frame: Day -1 and Day 2 of each treatment period ] Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for evaluation of hematology parameters including platelets, neutrophils, monocytes, lymphocytes, leucocyte, eosinophils and basophils. Mean Corpuscular Volume (MCV) at Indicated Time-points [ Time Frame: Day -1 and Day 2 (...) of each treatment period ] Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for evaluation of MCV. Mean Corpuscular Hemoglobin (MCH) at Indicated Time-points [ Time Frame: Day -1 and Day 2 of each treatment period ] Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for evaluation of MCH. Erythrocyte Count at Indicated Time-points [ Time Frame: Day -1 and Day 2 of each treatment period ] Blood samples

2018 Clinical Trials

185. Multiple-ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Healthy Male Subjects

hemoglobin concentration (MCHC) [ Time Frame: From baseline up to follow-up (5 to 7 days post last dose) ] To assess the MCHC as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension. Laboratory assessments: Hematology - Mean corpuscular volume (MCV) [ Time Frame: From baseline up to follow-up (5 to 7 days post last dose) ] To assess the MCV as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension. Laboratory (...) up to follow-up (5 to 7 days post last dose) ] To assess the Hb as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension. Laboratory assessments: Hematology - Mean corpuscular hemoglobin (MCH) [ Time Frame: From baseline up to follow-up (5 to 7 days post last dose) ] To assess the MCH as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension. Laboratory assessments: Hematology - Mean corpuscular

2018 Clinical Trials

186. Peer Support in Diabetes Management

at 6 and 12 months [ Time Frame: Baseline, 6 months, 12 months ] Hemoglobin (g/L) Change from Baseline Red Blood Cell Count at 6 and 12 months [ Time Frame: Baseline, 6 months, 12 months ] Red blood cell count (10^12/L) Change from Baseline Mean Corpuscular Volume at 6 and 12 months [ Time Frame: Baseline, 6 months, 12 months ] Mean Corpuscular Volume (fL) Change from Baseline Mean Corpuscular Hemoglobin at 6 and 12 months [ Time Frame: Baseline, 6 months, 12 months ] Mean Corpuscular Hemoglobin (...) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03437525 Recruitment Status : Active, not recruiting First Posted : February 19, 2018 Last Update Posted : February 19, 2018 Sponsor: Shanghai 6th People's Hospital Collaborators: University of North Carolina, Chapel Hill Asian Center for Health Education

2018 Clinical Trials

187. A Study to Evaluate the Safety, Tolerability and Study Drug Absorption to the Blood After Administration of Single Ascending Doses of AZD8154 in Healthy Participants.

by assessment of mean cell volume (MCV). Safety and tolerability of AZD8154 by assessment of clinical Laboratory evaluations-mean corpuscular hemoglobin (MCH) [ Time Frame: From baseline up to follow-up visit (6 days post final dose) ] Safety and tolerability of AZD8154 by assessment of mean corpuscular hemoglobin (MCH). Safety and tolerability of AZD8154 by assessment of clinical Laboratory evaluations-mean corpuscular hemoglobin concentration (MCHC) [ Time Frame: From baseline up to follow-up visit (6 (...) and tolerability of AZD8154 by assessment of HCT. Safety and tolerability of AZD8154 by assessment of clinical Laboratory evaluations-platelets [ Time Frame: From baseline up to follow-up visit (6 days post final dose) ] Safety and tolerability of AZD8154 by assessment of platelets. Safety and tolerability of AZD8154 by assessment of clinical Laboratory evaluations-mean cell volume (MCV) [ Time Frame: From baseline up to follow-up visit (6 days post final dose) ] Safety and tolerability of AZD8154

2018 Clinical Trials

188. Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents

count, neutrophils, white blood cell count, lymphocytes, hemoglobin, monocytes, hematocrit, eosinophils, mean corpuscular volume, basophils, and mean corpuscular hemoglobin. Number of subjects with abnormal findings for clinical chemistry laboratory parameters through 144 weeks [ Time Frame: Up to 144 weeks ] Blood samples will be collected from subjects for analysis of clinical chemistry parameters including blood urea nitrogen, potassium, aspartate aminotransferase, total bilirubin, creatinine (...) parameters through 96 weeks [ Time Frame: Up to 96 weeks ] Blood samples will be collected from subjects for analysis of hematology parameters including platelet count, red blood cell count, neutrophils, white blood cells, lymphocytes, hemoglobin, monocytes, hematocrit, eosinophils, mean corpuscular volume, basophils, and mean corpuscular hemoglobin. Number of subjects with abnormal findings for clinical chemistry laboratory parameters through 96 weeks [ Time Frame: Up to 96 weeks ] Blood samples

2018 Clinical Trials

189. A Safety and Tolerability Study of RJX Drug Product in Healthy Participants

to Day 5 ] Hematology Parameters include: hemoglobin, hematocrit, red blood cell count, white blood cell, platelet count, white blood cell subset count (neutrophils, eosinophils, basophils, lymphocytes, and monocytes), with differential count, mean corpuscular volume, mean corpuscular hemoglobin, mean cell hemoglobin concentration. Observed values and actual changes from baseline of continuous clinical chemistry parameters will be summarized descriptively, by actual treatment/dose level and visit (...) /time point. Categorical outcomes will be summarized by frequency tabulations. Part 2: Number of participants with hematology values of potential clinical importance criteria (PCC). [ Time Frame: Up to Day 12 ] Hematology Parameters include: hemoglobin, hematocrit, red blood cell count, white blood cell, platelet count, white blood cell subset count (neutrophils, eosinophils, basophils, lymphocytes, and monocytes), with differential count, mean corpuscular volume, mean corpuscular hemoglobin, mean

2018 Clinical Trials

190. Pilot Immunotherapy With Autologous T-cells Specific for New York Esophageal Antigen-1 (NY-ESO-1)/ Cancer-testis Antigen-2 (LAGE-1a)-Positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab

corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), reticulocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, red blood cell count (RBC), hemoglobin and hematocrit. Number of subjects with abnormal findings for clinical chemistry parameters [ Time Frame: Up to 106 weeks ] Blood samples will be collected for analysis of clinical chemistry parameters including blood urea nitrogen (BUN), potassium, AST, total and direct bilirubin, creatinine, sodium, ALT, total protein, glucose (...) Alone or in Combination With Pembrolizumab The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03709706 Recruitment Status : Recruiting First Posted : October 17, 2018 Last Update Posted : February 11, 2019 See Sponsor

2018 Clinical Trials

191. Safety and tolerability of carvacrol in healthy subjects: a phase I clinical study. (PubMed)

the measured variables. In the group receiving 1 mg/kg/day carvacrol, calcium, erythrocyte sedimentation rate (ESR), mean cell volume (MCV), hemoglobin (Hb), and hematocrit (HCT) levels were significantly reduced but creatinine phosphokinase (CPK) was significantly increased, after treatment compared to baseline values (p < 0.05-p < 0.001). There was significant reductions in high-density lipoprotein cholesterol (HDL), total bilirubin, amylase, iron, red blood cells (RBC) count, and HCT after one-month (...) treatment with 2 mg/kg/day carvacrol compared to pretreatment values (p < 0.05-p < 0.01). Although, triglyceride (TG), phosphorus, lactate dehydrogenase (LDH), prothrombin time (PT), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC) were significantly increased after treatment with carvacrol 1 mg/kg/day (p < 0.05-p < 0.001), all post-treatment measured parameters were within normal range. Treatment with carvacrol 2 mg/kg/day for one month increased FEV1 (p < 0.05

2018 Drug and chemical toxicology

192. Hematological parameters in Ghanaian sickle cell disease patients (PubMed)

corpuscular Hb, mean cell volume, mean corpuscular Hb concentration, and white blood cells (WBC) and platelet (PLT) counts were recorded.WBC and PLT counts were significantly higher in both female and male patients with SCD, compared with their healthy counterparts (P<0.05). The level of WBC was, however, significantly higher in patients with HbSS VOC among the SCD patients (P<0.001). Levels of Hb, RBC, and hematocrit were significantly higher in the controls (P<0.001). There was no significant difference (...) controls at a teaching hospital in Ghana.This was a cross-sectional study involving a total of 628 subjects, including 148 HbAA controls, 208 HbSS patients in steady state, 82 HbSC patients in steady state, 156 HbSS patients in vaso-occlusive crises (VOC), and 34 HbSC patients in VOC. Venous blood sample was collected from all study participants. A full blood count was done within 2 hours of collection, and hemoglobin (Hb) concentration, packed cell volume, red blood cell (RBC) concentration, mean

Full Text available with Trip Pro

2018 Journal of blood medicine

193. Common α-globin variants modify hematologic and other clinical phenotypes in sickle cell trait and disease (PubMed)

blood cell parameters, anemia, and chronic kidney disease (CKD). In a community-based cohort of 2,916 African Americans from the Jackson Heart Study, we confirmed the expected associations between SCT, HbC trait, and the -α3.7 deletion with lower mean corpuscular volume/mean corpuscular hemoglobin and higher red blood cell count and red cell distribution width. In addition to the recently recognized association of SCT with lower estimated glomerular filtration rate and glycated hemoglobin (HbA1c

Full Text available with Trip Pro

2018 PLoS genetics

194. The Effects of Ramadan-Fasting (RF) on Inflammatory and Hematological Indices of Stable Chronic Obstructive Pulmonary Disease (COPD) Male Patients: A Pilot Study (PubMed)

fasted during Ramadan 2017 volunteered for the study. Three sessions (Before-Ramadan, End-Ramadan and After-Ramadan) were selected. Spirometry tests and blood samples were consistently performed 2.5-4.5 hr before the interruption of the fasting. Assessment sessions comprised: spirometry, inflammatory [erythrocyte sedimentation rate (ESR); C-reactive protein (CRP)] and hematological [red and white blood cells (RBC, WBC); hemoglobin; hematocrit; mean corpuscular volume; mean corpuscular hemoglobin (...) The Effects of Ramadan-Fasting (RF) on Inflammatory and Hematological Indices of Stable Chronic Obstructive Pulmonary Disease (COPD) Male Patients: A Pilot Study No previous study has evaluated the effects of RF on inflammatory and hematological indices of COPD patients. The main objective of the present pilot study was to assess the effects of RF on some inflammatory and hematological indices measured in male patients with stable COPD. Fifteen COPD patients (mean ± SD of age: 71 ± 6 years) who

Full Text available with Trip Pro

2018 American journal of men's health

195. Diagnostic value of oral “beefy red” patch in vitamin B12 deficiency (PubMed)

ulcers. Patients underwent clinical examination and laboratory investigations, including complete blood count and estimation of serum B12, folate, iron, and ferritin levels. Resolution of clinical signs and symptoms after 1 month of B12 supplement was regarded as the diagnostic gold standard.Of 136 patients, 70 had B12 deficiency. Among these patients, the oral "beefy red" patch was observed in 61, abnormal mean corpuscular volume (MCV) was noted in 30, and serum cobalamin levels <200 and <350 pg/mL

Full Text available with Trip Pro

2018 Therapeutics and clinical risk management

196. Haematology of N’Dama and West African Shorthorn cattle herds under natural Trypanosoma vivax challenge in Ghana (PubMed)

-specific primers were used to diagnose T. vivax infection in an N'Dama herd at Cape Coast in southern Ghana and a WASH herd at Chegbani in northern Ghana from May to July 2011 in a cross-sectional study. Levels of haematological parameters comprising packed cell volume (PCV), haemoglobin (Hb) concentration and red blood cell (RBC) and total white blood cell (TWBC) counts; differential WBC counts (neutrophils, lymphocytes, eosinophils, monocytes and basophils); and RBC indices of mean corpuscular volume (...) (MCV), mean corpuscular haemoglobin (MCH) and mean corpuscular haemoglobin concentration (MCHC) were determined in blood samples and then compared between infected and uninfected cattle. Results: We found that haematological indices for infected and uninfected animals in both breeds were within the normal range. However, the mean PCV values for T. vivax-infected WASH and N'Dama were lower in infected compared to uninfected animals. The difference was significant ( p< 0.05) in N'Dama but not in WASH

Full Text available with Trip Pro

2018 F1000Research

197. Thalassemia minor presenting with vitamin B12 deficiency, paraparesis, and microcytosis (PubMed)

and homocysteine levels. However, her complete blood count showed no evidence of anemia or macrocytosis; instead, her mean corpuscular volume was low. Hemoglobin electrophoresis showed thalassemia trait, and that probably masked the megaloblastic features of vitamin B12 deficiency. She responded fully to vitamin B12 replacement therapy.

Full Text available with Trip Pro

2018 Journal of blood medicine

198. Quantification of stored red blood cell fluctuations by time-lapse holographic cell imaging (PubMed)

and dimple sections separately. The measurements show that healthy RBCs that maintain their discocyte shape become stiffer with storage time. The correlation analysis demonstrates a significant negative correlation between CMFs and the sphericity coefficient, which characterizes the morphological type of erythrocyte. In addition, we show the correlation results between CMFs and other morphological properties such as projected surface area, surface area, mean corpuscular volume, and mean corpuscular

Full Text available with Trip Pro

2018 Biomedical optics express

199. Elevated red blood cell distribution width predicts poor prognosis in patients with oral squamous cell carcinoma (PubMed)

%, with a range from 11.6% to 24.5%. The RDW was found to be significantly correlated with node metastasis, tumor length, and TNM stage (P<0.05 for all). As for biochemical parameters, the results showed that higher RDW values were significantly associated with hemoglobin, mean corpuscular volume, white blood cell count, albumin, and C-reactive protein (P<0.01 for all). A significant association of RDW with the tumor marker cytokeratin 19 fragments (CYFRA21-1) and squamous cell carcinoma antigen (SCC-Ag

Full Text available with Trip Pro

2018 Cancer management and research

200. Red blood cell distribution width in pregnancy: a systematic review (PubMed)

Red blood cell distribution width in pregnancy: a systematic review Anisocytosis has been associated with the severity and prognosis of several acute and chronic diseases, as well as physiological conditions such as pregnancy. Anisocytosis is quantified by the red blood cell distribution width (RDW), expressed as the ratio, multiplied by 100, between the standard deviation (SD) of red blood cell volumes and the mean corpuscular volume, or as the SD of erythrocyte volumes (RDW-SD). The aim

Full Text available with Trip Pro

2018 Biochemia medica

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>